Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Advances and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System
New skin disease treatments using TDDS are improving but face challenges like side effects and high costs.
research Thyroid Hormone Receptor Agonist Promotes Hair Growth in Mice
TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
research Sustainable UV Approaches Supported by Greenness and Whiteness Assessments for Estimating a Recently FDA-Approved Combination for Managing Urologic Disorders: Tukey's Test
New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
research Microneedle Arrays Combined With Nanomedicine Approaches for Transdermal Delivery of Therapeutics
Microneedle arrays with nanotechnology show promise for painless drug delivery through the skin but need more research on safety and effectiveness.
Community Join
5 / 57 resultscommunity Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
community TDM-105795, a new hair loss treatment that actually works!
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.